These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16700717)

  • 1. EUCAST Technical Note on daptomycin.
    European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee
    Clin Microbiol Infect; 2006 Jun; 12(6):599-601. PubMed ID: 16700717
    [No Abstract]   [Full Text] [Related]  

  • 2. EUCAST Technical Note on linezolid.
    European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee
    Clin Microbiol Infect; 2006 Dec; 12(12):1243-5. PubMed ID: 17121637
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.
    Rose WE; Rybak MJ; Kaatz GW
    J Antimicrob Chemother; 2007 Aug; 60(2):334-40. PubMed ID: 17540670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
    DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
    Alder J
    Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
    Mariani PG; Sader HS; Jones RN
    J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029
    [No Abstract]   [Full Text] [Related]  

  • 7. Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers.
    Picazo JJ; Betriu C; Culebras E; Rodríguez-Avial I; Gómez M; López F;
    Diagn Microbiol Infect Dis; 2009 Aug; 64(4):448-51. PubMed ID: 19631100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.
    Silverman JA; Mortin LI; Vanpraagh AD; Li T; Alder J
    J Infect Dis; 2005 Jun; 191(12):2149-52. PubMed ID: 15898002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Daptomycin. Reassessment of an antibiotic].
    Gobernado M
    Rev Esp Quimioter; 2007 Mar; 20(1):11-8. PubMed ID: 17530032
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients.
    Kratzer C; Rabitsch W; Hirschl AM; Graninger W; Presterl E
    Eur J Haematol; 2007 Nov; 79(5):405-9. PubMed ID: 17714506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ["Bacteriostatic test"- a method of the study of microbial sensitivity to antibiotics].
    Rachinskiĭ SV; Zakhidova EKh
    Lab Delo; 1974; (12):732-5. PubMed ID: 4140963
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term use of daptomycin for MRSA osteomyelitis and joint infection.
    Burns CA
    Scand J Infect Dis; 2008; 40(2):183-6. PubMed ID: 17852899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activities of daptomycin, tigecycline, linezolid and eight other antibiotics, alone and in combination, against 41 Staphylococcus spp. clinical isolates from bone and joint infections.
    Kuli B; de Barbeyrac B; Dauchy FA; Dutronc H; Bébéar C; Mégraud F; Dupon M
    Int J Antimicrob Agents; 2009 May; 33(5):491-3. PubMed ID: 19153031
    [No Abstract]   [Full Text] [Related]  

  • 14. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreasing the probability of creatine phosphokinase elevations: clinical considerations for daptomycin dosing in obese patients.
    Donovan BJ; Mohr JF; Knapp AG; Eisenstein BI
    Clin Infect Dis; 2010 Oct; 51(8):989; author reply 989-90. PubMed ID: 20858080
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro activity of daptomycin against methicillin- and multi-resistant Staphylococcus haemolyticus invasive isolates carrying different mec complexes.
    Campanile F; Bongiorno D; Borbone S; Falcone M; Giannella M; Venditti M; Stefani S
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):227-31. PubMed ID: 18329218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-clinical experience with daptomycin.
    Hawkey PM
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.
    Boucher HW; Sakoulas G
    Clin Infect Dis; 2007 Sep; 45(5):601-8. PubMed ID: 17682996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005).
    Pfaller MA; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):459-65. PubMed ID: 17240105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.